Tildrakizumab Safe, Efficacious for Treating Active Psoriatic Arthritis
A phase 2b study showed that tildrakizumab was significantly more efficacious than placebo in treatment of joint and skin manifestations of psoriatic arthritis by week 24.
EULAR 2019
Ixekizumab May Be Superior to Adalimumab in bDMARD-Naive Patients With PsA
Open-label head-to-head trial compared efficacy and safety of ixekizumab with adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs.
Live-Attenuated Vaccines Appear Safe for Children With Rheumatic Diseases
Investigators examined retrospective data of patients with juvenile idiopathic arthritis and other diseases who received live booster MMR or MMR + varicella while taking disease-modifying antirheumatic drugs, glucocorticosteroids or biological agents.
Efficacy of Filgotinib in Methotrexate-Naive Patients With Rheumatoid Arthritis
Study compared efficacy and safety of filgotinib with and without methotrexate in patients with rheumatoid arthritis who were naive to methotrexate therapy.
Ultrasound Findings Predict Arthritis Development Among ACPA+ Individuals With Pain
Investigators sought to determine the efficacy of ultrasound to forecast the development of arthritis among patients with anti-citrullinated protein antibodies with musculoskeletal pain.
Secukinumab Improves Axial Manifestations in Psoriatic Arthritis
MAXIMISE is an ongoing study evaluating the efficacy and safety of secukinumab 300 mg or 150mg in managing axial manifestations in patients with psoriatic arthritis.
Gout Associated With Hospitalizations for CV and Renal Complications
As previous studies indicated that all-cause hospitalizations in patients with gout in the United States have overwhelmingly increased by 410% in the last 22 years, researchers sought to determine the potential reasons for the excess hospitalizations.
-
Loading...
-
Loading...
Next post in EULAR 2019 Coverage
